UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.118

Sortiert nach

Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

Intensive care medicine, 2020-07, Vol.46 (7), p.1425-1437

2020

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial

Clinical infectious diseases, 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

Role of rsbU and Staphyloxanthin in Phagocytosis and Intracellular Growth of Staphylococcus aureus in Human Macrophages and Endothelial Cells

The Journal of infectious diseases, 2009-11, Vol.200 (9), p.1367-1370

2009

Link zum Volltext

Verfügbarkeit prüfen

The Notch ligand delta-1 is a hematopoietic development cofactor for plasmacytoid dendritic cells

Blood, 2006-04, Vol.107 (7), p.2694-2701

2006

Link zum Volltext

Verfügbarkeit prüfen

Restoration of Susceptibility of Intracellular Methicillin-Resistant Staphylococcus aureus to β-Lactams: Comparison of Strains, Cells, and Antibiotics

Antimicrobial Agents and Chemotherapy, 2008-08, Vol.52 (8), p.2797-2805

2008

Link zum Volltext

Verfügbarkeit prüfen

TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help

Blood, 2007-06, Vol.109 (12), p.5318-5326

2007

Link zum Volltext

Verfügbarkeit prüfen

Variation in morphology and performance of predator-sensing system in wild cricket populations

Journal of experimental biology, 2005-02, Vol.208 (Pt 3), p.461-468

2005

Link zum Volltext

Verfügbarkeit prüfen

TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20

Blood, 2011-11, Vol.118 (21), p.2730-2730

2011

Link zum Volltext

Verfügbarkeit prüfen

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

The New England journal of medicine, 2012-12, Vol.367 (24), p.2284-2295

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

PLoS medicine, 2014-07, Vol.11 (7), p.e1001685

2014

Link zum Volltext

Verfügbarkeit prüfen

Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

BMJ open, 2021-07, Vol.11 (7), p.e042921-e042921

2021

Link zum Volltext

Verfügbarkeit prüfen

The adjuvant effect of TLR agonists on CD4+ effector T cells is under the indirect control of regulatory T cells

European journal of immunology, 2011-08, Vol.41 (8), p.2303-2313

2011

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial

Clinical infectious diseases, 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

Publication de la littérature. Entretiens croisés avec Olivier Chaudenson, Jean-Max Colard, Olivier Marbœuf et Aurélie Olivier

Littérature (Paris. 1971), 2018-12 (192), p.96-111

2018

Link zum Volltext

Verfügbarkeit prüfen

A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition

British journal of clinical pharmacology, 2018-10, Vol.84 (10), p.2270-2279

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.969)
Mit Volltextzugriff
(1.961)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.915)
Französisch
(222)
Japanisch
(185)
Deutsch
(4)
Spanisch
(2)
Norwegisch
(1)
Russisch
(1)

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

Role of rsbU and Staphyloxanthin in Phagocytosis and Intracellular Growth of Staphylococcus aureus in Human Macrophages and Endothelial Cells

The Notch ligand delta-1 is a hematopoietic development cofactor for plasmacytoid dendritic cells

Restoration of Susceptibility of Intracellular Methicillin-Resistant Staphylococcus aureus to β-Lactams: Comparison of Strains, Cells, and Antibiotics

TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help

Variation in morphology and performance of predator-sensing system in wild cricket populations

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children

TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

Safety of the Malaria Vaccine Candidate, RTS,S/AS01.sub.E in 5 to 17 Month Old Kenyan and Tanzanian Children

Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

The adjuvant effect of TLR agonists on CD4+ effector T cells is under the indirect control of regulatory T cells

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons

T Cell Responses to the RTS,S/AS01E and RTS,S/AS02D Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children

T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children

Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons

Publication de la littérature. Entretiens croisés avec Olivier Chaudenson, Jean-Max Colard, Olivier Marbœuf et Aurélie Olivier

Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)

Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial

A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children

Suchergebnisse filtern